79 related articles for article (PubMed ID: 27089226)
21. E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma.
Tarhini AA; Lee SJ; Li X; Rao UNM; Nagarajan A; Albertini MR; Mitchell JW; Wong SJ; Taylor MA; Laudi N; Truong PV; Conry RM; Kirkwood JM
Clin Cancer Res; 2019 Jan; 25(2):524-532. PubMed ID: 30420448
[TBL] [Abstract][Full Text] [Related]
22. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
[TBL] [Abstract][Full Text] [Related]
23. Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.
Atkins MB; Hodi FS; Thompson JA; McDermott DF; Hwu WJ; Lawrence DP; Dawson NA; Wong DJ; Bhatia S; James M; Jain L; Robey S; Shu X; Homet Moreno B; Perini RF; Choueiri TK; Ribas A
Clin Cancer Res; 2018 Apr; 24(8):1805-1815. PubMed ID: 29358500
[No Abstract] [Full Text] [Related]
24. Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518.
Yao JC; Guthrie KA; Moran C; Strosberg JR; Kulke MH; Chan JA; LoConte N; McWilliams RR; Wolin EM; Mattar B; McDonough S; Chen H; Blanke CD; Hochster HS
J Clin Oncol; 2017 May; 35(15):1695-1703. PubMed ID: 28384065
[TBL] [Abstract][Full Text] [Related]
25. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.
Hege KM; Bergsland EK; Fisher GA; Nemunaitis JJ; Warren RS; McArthur JG; Lin AA; Schlom J; June CH; Sherwin SA
J Immunother Cancer; 2017; 5():22. PubMed ID: 28344808
[TBL] [Abstract][Full Text] [Related]
26. Interferon-induced IFIT5 promotes epithelial-to-mesenchymal transition leading to renal cancer invasion.
Lo UG; Bao J; Cen J; Yeh HC; Luo J; Tan W; Hsieh JT
Am J Clin Exp Urol; 2019; 7(1):31-45. PubMed ID: 30906803
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of COL5A1 promotes tumor progression and metastasis and correlates with poor survival of patients with clear cell renal cell carcinoma.
Feng G; Ma HM; Huang HB; Li YW; Zhang P; Huang JJ; Cheng L; Li GR
Cancer Manag Res; 2019; 11():1263-1274. PubMed ID: 30799953
[TBL] [Abstract][Full Text] [Related]
28. Interferon beta induces apoptosis in nasopharyngeal carcinoma cells
Makowska A; Wahab L; Braunschweig T; Kapetanakis NI; Vokuhl C; Denecke B; Shen L; Busson P; Kontny U
Oncotarget; 2018 Mar; 9(18):14228-14250. PubMed ID: 29581840
[TBL] [Abstract][Full Text] [Related]
29. Decreased expression of EphA5 is associated with Fuhrman nuclear grade and pathological tumour stage in ccRCC.
Wang X; Xu H; Wu Z; Chen X; Wang J
Int J Exp Pathol; 2017 Feb; 98(1):34-39. PubMed ID: 28421649
[TBL] [Abstract][Full Text] [Related]
30. Defining risk status in the first-line treatment of metastatic renal cell carcinoma.
Schmidinger M; Zielinski CC
J Cancer Res Clin Oncol; 2010 Jul; 136(7):961-8. PubMed ID: 20454802
[TBL] [Abstract][Full Text] [Related]
31. First-line ICIs in renal cell carcinoma.
Fiorentino V; Tralongo P; Larocca LM; Pizzimenti C; Martini M; Pierconti F
Hum Vaccin Immunother; 2023 Aug; 19(2):2225386. PubMed ID: 37395601
[TBL] [Abstract][Full Text] [Related]
32. Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy.
Kawano Y; Takahashi W; Eto M; Kamba T; Miyake H; Fujisawa M; Kamai T; Uemura H; Tsukamoto T; Azuma H; Matsubara A; Nishimura K; Nakamura T; Ogawa O; Naito S
Cancer Sci; 2016 Jul; 107(7):1013-7. PubMed ID: 27089226
[TBL] [Abstract][Full Text] [Related]
33. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
[TBL] [Abstract][Full Text] [Related]
34. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma.
Ito N; Eto M; Nakamura E; Takahashi A; Tsukamoto T; Toma H; Nakazawa H; Hirao Y; Uemura H; Kagawa S; Kanayama H; Nose Y; Kinukawa N; Nakamura T; Jinnai N; Seki T; Takamatsu M; Masui Y; Naito S; Ogawa O
J Clin Oncol; 2007 Jul; 25(19):2785-91. PubMed ID: 17602083
[TBL] [Abstract][Full Text] [Related]
35. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
[TBL] [Abstract][Full Text] [Related]
36. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
